Oxagen is focused on becoming a significant biopharmaceutical company, developing a pipeline of novel drugs to treat inflammatory diseases. The Company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and selected the most promising as drug targets.
Oxagen was established in April 1997 and initially focused on identifying drug targets through genetics. Since 2003 the Company has focused on building a drug discovery and development capability and pipeline around GPCR targets. Oxagen’s lead compound OC000459 is a novel oral anti-inflammatory agent for the treatment of allergic disease and has successfully completed Phase IIa trials demonstrating efficacy in both asthma and allergic rhinitis. Phase IIb dose-range finding studies are currently underway. The Company is based in Milton Park, south of Oxford.
High throughput polymorphism mapping and genotyping, robotics and functional genomics.
| Contact Details: |
| 91 Milton Park |
| Abingdon |
| Oxfordshire |
| OX14 4RY |
| United Kingdom |
| Tel: | +44 1235 443300 |
| Fax: | +44 1235 443301 |
| Email: | oxagen@oxagen.co.uk |
| WWW: | www.oxagen.co.uk
|
|
Loading...
|
Recent Publications by Oxagen Limited: |  |
Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway.
It is now well established that interaction of PGD(2) with chemoattractant... | 26th June, 2009
| Oxagen
| J Immunol. 2009 Jun 15;182(12):7580-6.
DOI Direct Link |
Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells.
The mechanisms by which immunologically activated mast cells stimulate the... | 17th June, 2009
|
| Clin Exp Immunol. 2009 Apr;156(1):126-33. Epub 2009 Feb 11.
DOI Direct Link |
Antagonists of the prostaglandin D2 receptor CRTH2.
Prostaglandin D(2) (PGD(2)) is produced by mast cells, Th2 lymphocytes and... | 16th January, 2009
| Pharmacology, Oxagen
| Drug News Perspect. 2008 Jul-Aug;21(6):317-22.
DOI Direct Link |
Use of commercially available radiation hybrid panels.
Several panels are available for puchase, and this unit provides update... | 24th May, 2008
| Oxagen, Ltd., Abingdon, United Kingdom.
| Curr Protoc Hum Genet. 2001 May;Chapter 3:Unit 3.5.
DOI Direct Link |
The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses.
Prostaglandin D(2) (PGD(2)) is produced by mast cells, Th2 lymphocytes and... | 29th April, 2008
| Oxagen Ltd, 91 Milton
| Br J Pharmacol. 2008 Mar;153 Suppl 1:S191-9. Epub 2007 Oct 29.
DOI Direct Link |
→View more Oxagen Limited research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 853 times since April 2007, the link to the organisation's website has been followed 81 times
Recent Search Terms used to find this page: OC000459 | oxagen vastox abingdon | Oxagen Ltd | Oxagen Limited | Oxagen | .
Search for more companies in Abingdon
Search for more companies in Oxfordshire
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Oxagen Limited
